重症监护终末期患者疼痛管理的临床实践指南与共识声明:系统评价
该系统评价检索PubMed、EMBASE、Cochrane系统评价数据库和Biblioteca Virtual en Salud自建库至2019年3月28日的文献,纳入10篇临床实践指南、共识声明和质量基准。采用AGREE II工具评估质量,多个领域评分低,尤其是适用性和制定严谨性。多数文件在五个主题上一致:使用量化工具评估疼痛;阿片类缓解疼痛、苯二氮䓬类缓解焦虑;撤除生命支持期间反对使用神经肌肉阻滞剂以评估疼痛;认可使用高剂量阿片类和镇静剂控制疼痛,不顾及可能加速死亡的风险;使用质量指标改善ICU终末期疼痛管理。作者据此提出管理算法以改善濒死危重患者的整体照护。
要点
- 多数指南/共识一致推荐使用量化工具评估ICU终末期患者的疼痛。
- 多数指南/共识一致推荐阿片类用于缓解疼痛、苯二氮䓬类用于缓解焦虑。
- 多数指南/共识一致反对在撤除生命支持期间使用神经肌肉阻滞剂以评估疼痛。
- 多数指南/共识认可使用高剂量阿片类和镇静剂控制疼痛,不顾及可能加速死亡的风险。
- 多数指南/共识一致推荐使用质量指标改善ICU终末期疼痛管理。
适用人群与场景
- ICU终末期(濒死)危重患者。
处置流程与药物剂量
- 使用量化工具评估疼痛。
- 使用阿片类缓解疼痛、苯二氮䓬类缓解焦虑。
- 撤除生命支持期间反对使用神经肌肉阻滞剂以评估疼痛。
- 认可使用高剂量阿片类和镇静剂控制疼痛,不顾及可能加速死亡的风险。
- 使用质量指标改善ICU终末期疼痛管理。
- 作者基于研究结果提出管理算法以改善濒死危重患者的整体照护。
研究设计与关键结果
- 系统评价纳入10篇出版物(临床实践指南、共识声明和质量基准),检索截至2019年3月28日。
- AGREE II评估显示多个质量领域评分低,尤其是适用性和制定严谨性。
- 多数文件在五个主题上达成一致:量化疼痛评估、阿片类镇痛/苯二氮䓬类抗焦虑、撤除生命支持时反对神经肌肉阻滞剂、认可高剂量阿片类和镇静剂不顾加速死亡风险、使用质量指标。
证据类型、等级与局限
- 证据类型:系统评价。
- 局限:缺乏高质量证据;AGREE II评估显示多个质量领域评分低,尤其是适用性和制定严谨性。
对床旁实践的改变
- 作者认为,尽管缺乏高质量证据,ICU终末期疼痛管理推荐是同质的,并由伦理原则和专家一致意见支持。
- 作者认为,考虑到姑息治疗团队参与ICU濒死患者管理的需求日益增长,需要明确其早期参与并进一步制定全面的循证疼痛管理策略。
- 作者基于研究结果提出管理算法以改善濒死危重患者的整体照护。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To identify and synthesize available recommendations from scientific societies and experts on pain management at the end-of-life in the ICU.
DATA SOURCES: We conducted a systematic review of PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and Biblioteca Virtual en Salud from their inception until March 28, 2019.
STUDY SELECTION: We included all clinical practice guidelines, consensus statements, and benchmarks for quality.
DATA EXTRACTION: Study selection, methodological quality, and data extraction were performed independently by two investigators. A quality assessment was performed by four investigators using the Appraisal of Guidelines for Research and Evaluation II instrument. The recommendations were then synthesized and categorized.
DATA SYNTHESIS: Ten publications were included. The Appraisal of Guidelines for Research and Evaluation II statement showed low scores in various quality domains, especially in the applicability and rigor of development. Most documents were in agreement on five topics: 1) using a quantitative tool for pain assessment; 2) administering narcotics for pain relief and benzodiazepines for anxiety relief; 3) against prescribing neuromuscular blockers during withdrawal of life support to assess pain; 4) endorsing the use of high doses of opioids and sedatives for pain control, regardless of the risk that they will hasten death; and 5) using quality indicators to improve pain management during end-of-life in the ICU.
CONCLUSIONS: In spite of the lack of high-quality evidence, recommendations for pain management at the end-of-life in the ICU are homogeneous and are justified by ethical principles and agreement among experts. Considering the growing demand for the involvement of palliative care teams in the management of the dying patients in the ICU, there is a need to clearly define their early involvement and to further develop comprehensive evidence-based pain management strategies. Based on the study findings, we propose a management algorithm to improve the overall care of dying critically ill patients.
参考来源
- Durán-Crane A, Laserna A, López-Olivo MA, et al. Clinical Practice Guidelines and Consensus Statements About Pain Management in Critically Ill End-of-Life Patients: A Systematic Review. Crit Care Med. 2019. PMID: 31517694. doi:10.1097/CCM.0000000000003975
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。